Literature DB >> 11964083

Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro.

Claudia Rudroff1, Stefan Seibold, Roland Kaufmann, Cecilia Cu Zetina, Kathrin Reise, Ute Schäfer, Annette Schneider, Michael Brockmann, Johannes Scheele, Edmund A M Neugebauer.   

Abstract

Patients with pancreatic cancer frequently suffer from thrombosis due to excess thrombin generation. Yet, the effects of thrombin on pancreatic cancer are still poorly understood. The thrombin receptor PAR-1 is responsible for cellular effects of thrombin. PAR-1 plays an important role in the progression of different solid tumours in vitro. In breast cancer the level of PAR-1 expression correlates with invasiveness. Our aim was to correlate PAR-1 mRNA and protein expression level with the grade of differentiation of pancreatic tissue and cancer cell lines. PAR-1 protein was not detectable in the epithelium of healthy pancreas. Analysis of PAR-1 protein expression by immunofluorescence staining of pancreatic cancer cell lines revealed a correlation to the grade of differentiation. Quantitative analysis of PAR-1 protein expression by Western Blot analysis confirmed these observations. Analysis of PAR-1 mRNA expression showed low levels in healthy pancreas compared to pancreatic cancer tissue and the pancreatic cancer cell line MIA PaCa-2. The level of PAR-1 mRNA differed up to 25 fold between the respective pancreatic cancer cell lines. The eminent differences in PAR-1 expression, both protein and mRNA, between healthy pancreatic tissue and pancreatic cancer in vivo and in vitro emphasise the putative role of PAR-1 in pancreatic cancer progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964083     DOI: 10.1023/a:1014598904644

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  10 in total

1.  Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer.

Authors:  Jaroslaw Cisowski; Katie O'Callaghan; Athan Kuliopulos; John Yang; Nga Nguyen; Qing Deng; Eric Yang; Michael Fogel; Sarah Tressel; Caitlin Foley; Anika Agarwal; Stephen W Hunt; Tom McMurry; Larry Brinckerhoff; Lidija Covic
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

Review 2.  Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.

Authors:  Sarah L Tressel; Georgios Koukos; Boris Tchernychev; Suzanne L Jacques; Lidija Covic; Athan Kuliopulos
Journal:  Methods Mol Biol       Date:  2011

3.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.

Authors:  Dalila Darmoul; Valérie Gratio; Hélène Devaud; Thérèse Lehy; Marc Laburthe
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 4.  Proteinase activated-receptors-associated signaling in the control of gastric cancer.

Authors:  Silvia Sedda; Irene Marafini; Roberta Caruso; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 5.  Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer.

Authors:  Andrea Pia Elste; Iver Petersen
Journal:  J Mol Histol       Date:  2010-06-20       Impact factor: 2.611

6.  Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation.

Authors:  Franziska Mußbach; Petra Henklein; Martin Westermann; Utz Settmacher; Frank-D Böhmer; Roland Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-06       Impact factor: 4.553

7.  Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2.

Authors:  E Yang; J Cisowski; N Nguyen; K O'Callaghan; J Xu; A Agarwal; A Kuliopulos; L Covic
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

Review 8.  GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets.

Authors:  Krishna Sriram; Cristina Salmerón; Shu Z Wiley; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

9.  Parstatin, a novel protease-activated receptor 1-derived inhibitor of angiogenesis.

Authors:  Michael B Duncan; Raghu Kalluri
Journal:  Mol Interv       Date:  2009-08

Review 10.  The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues.

Authors:  Elena Campello; Anton Ilich; Paolo Simioni; Nigel S Key
Journal:  Br J Cancer       Date:  2019-07-22       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.